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Moadel and colleagues have explored the potential use of
18F-2-deoxy-2-fluoro-D-glucose (18F-FDG), a positron-
emitting agent, as a radiomolecular therapy in the manage-
ment of advanced breast cancer. In two separate
transgenic mouse models of breast cancer, they demon-
strated the feasibility and the efficacy of 18F-FDG as a
treatment for metastatic disease. After 18F-FDG treatment,
the mammary glands were removed from the mice and
were examined for evidence of tumor cell kill. Apoptotic
changes were observed in small tumors (<1cm) and
necrosis was observed in larger lesions. To determine what
the radiation dose would be in patients with breast cancer,
the authors extrapolated the preclinical information to the
fluorodeoxyglucose positron emission tomography (FDG
PET) images from five women with widely disseminated
breast cancer. The dose of radiation delivered was calcu-
lated according to the standard uptake value at the site of
disease. Moadel and colleagues conclude that 18F-FDG
therapy could be safely administered to these individuals
without the risk of significant red marrow toxicity [1].
Samarium 153 and strontium 89 are the only radiopharma-
ceutical agents to date that are used to treat women with
breast cancer. Both are approved for the management of
bone metastases, which develop in more than 70% of
women with advanced breast cancer and are the source
of significant morbidity. Both agents are most effective in
patients who have diffuse osteoblastic disease and who
are also treated with external beam radiation to areas of
significant tumor burden. These two available agents
appear to be equivalent in efficacy, although samar-
ium 153 may produce less myelosuppression [2,3].
Samarium 153 and strontium 89 may also provide mean-
ingful but short-lived palliation of bone pain. However,
bone metastases are rarely the sole site of metastatic
disease. An obvious advantage of 18F-FDG is that it could
be used to treat both skeletal disease and extra-skeletal
disease.
Presumably if a lesion can be imaged by FDG PET then it
can also be treated with 18F-FDG. Because FDG PET has
been shown to be superior to conventional radiography,
the Food and Drugs Administration has approved FDG
PET imaging in the staging of advanced breast cancer and
in the assessment of response to treatment [4–8]. In
women with locally advanced breast cancers, FDG PET
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Abstract
Preclinical studies suggest that 18F-2-deoxy-2-fluoro-D-glucose (18F-FDG) kills breast cancer cells
without significant marrow toxicity or parenchymal toxicity. Radiation dose calculations estimated from
fluorodeoxyglucose positron emission tomography images in women with metastatic disease indicate
that 18F-FDG should be a feasible and safe option in humans. Because the available radiotherapeutic
agents, strontium 89 and samarium 153 provide palliation to a limited population of women with bony
metastases, new radiopharmaceutical agents with broader applicability are needed. The development
of  18F-FDG as the first positron-emitting radiotherapeutic has the potential to be an innovative
treatment, not only in osteoblastic disease, but also in osteolytic disease and in soft tissue metastases.
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may be more accurate than computerized tomography in
identifying internal mammary and mediastinal nodes [9].
Similar to multiple myeloma, the bone lesions produced by
breast cancer may be purely osteolytic. In such instances
the serum alkaline phosphatase and bone scintigraphy
may be entirely normal. FDG PET may be more effective
than conventional radiography and bone scintigraphy in
identifying osteolytic disease [10]. If this is the case 18F-
FDG may prove superior to samarium 153 and stron-
tium 89. If FDG PET identifies disease with greater
resolution than conventional radiography, then presumably
18F-FDG may also be able to control more disease.
With our present resolution capabilities, FDG PET is
unlikely to supplant surgery for staging newly diagnosed
breast cancers. Sentinel node mapping appears to be
superior to FDG PET staging of the axilla as FDG PET is
unable to identify micrometastatic disease and small
amounts of macrometastatic disease in the axilla. It seems
unlikely at this time that 18F-FDG will have a role in the
treatment of early stage disease [11].
The uptake of 18F-FDG varies according to the tumor histol-
ogy, the microvasculature, the proliferative rate, the tumor
cell density and the degree of necrosis. 18F-FDG uptake
requires the tumor to have the ability both to incorporate
glucose into the cell and to phosphorylate glucose to
glucose-6-phosphate [12,13]. Breast cancer is a heteroge-
neous disease with distinct natural histories defined by his-
tologic type, by tumor grade, by the presence or absence of
hormone receptors and by the her-2 expression. Recogniz-
ing the variability of the disease, it is not surprising that
18F-FDG uptake varies from patient to patient and may even
vary from metastasis to metastasis in the same patient
[12,14]. Because the delivered dose of radiation is calcu-
lated by the standard uptake value, the differences in FDG
PET uptake have implications for determining the radiation
dose at different sites following 18F-FDG therapy.
Even in the palliative setting, the toxicity of treatment must
be minimized. At present, most of the women who receive
strontium 89 or samarium 153 already have some degree
of marrow compromise as a result of prior cytotoxic
therapy, external beam irradiation and tumor infiltration.
Even small doses of radiation to the red marrow may
impact blood counts.
Moadel and colleagues acknowledge that uptake of
18F-FDG by the brain is “impossible to avoid” and pro-
vides a dose of 570cGy [1]. Similarly muscle, both skele-
tal muscle and cardiac muscle, may incorporate 18F-FDG.
The muscle uptake of 18F-FDG may be decreased by the
patient fasting or by administering benzodiazepines.
Whether corticosteroids will decrease edema and inflam-
mation in the brain will need to be determined.
More than 80,000 women each year are diagnosed with
metastatic breast cancer. In this setting the goal of inter-
vention with chemotherapy and hormonal therapies is to
provide palliation. After hormonal therapies have been
exhausted, sequential single-agent chemotherapy is advo-
cated. Even combinations of cytotoxic chemotherapy do
not appear to alter patient survival. The addition of the
humanized antibody to the her-2 protein Herceptin has
recently been shown to improve survival when it is
co-administered with first-line chemotherapy [15].
Newer agents that are targeted at unique aspects of
tumor biology are the hope for the future. These targeted
agents are often used in conjunction with conventional
agents. 18F-FDG will possibly be used in combination with
other systemic therapies. The refinement of ways to target
radiation therapy to the tumor is an important avenue to
pursue. Moadel and colleagues are to be congratulated
for taking the steps to develop a positron-emitting agent
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